Swimmer plot of the duration of response in patients receiving subcutaneous daratumumab injection. Responses shown from baseline to study week 24, where week 1 is the week of the first daratumumab treatment. The colors indicate platelet count: <30 × 109/L (red); 30 × 109/L to 50 × 109/L (yellow); >50 × 109/L (blue). Black line indicates exposure to corticosteroids, including those used as a concomitant therapy and as a part of daratumumab premedication. At the point of evaluation of response, concomitant therapy was administered to 8 of 21 patients, including TPO-RA only (n = 1), corticosteroids (n = 2), both (n = 4), and TPO-RA with sirolimus (n = 1). At the point of evaluation for sustained response, concomitant therapy was administered to 8 of 21 patients, including TPO-RA (n = 3), corticosteroids (n = 1), both (n = 2), mycophenolate mofetil (n = 1), and TPO-RA with sirolimus (n = 1); none were responders.
